عرض بسيط للتسجيلة

المؤلفRahhal, Alaa
المؤلفNajim, Mostafa
المؤلفAljundi, Amer Hussein
المؤلفMahfouz, Ahmed
المؤلفAlyafei, Sumaya Mehdar
المؤلفAwaisu, Ahmed
المؤلفHabib, Mhd, Baraa
المؤلفObeidat, Ibrahim
المؤلفFaisal, Mohanad Mohammed
المؤلفAlanzi, Meshaal Ali
المؤلفNair, Arun Prabhakaran
المؤلفElhassan, Areeg
المؤلفAl-Dushain, Abdullah
المؤلفAbdelmajid, Alaaeldin Abdelmajid
المؤلفAbdelgader, Ahmed Elfadil
المؤلفMoursi, Ahmed Mahmoud Ahmed
المؤلفAlharafsheh, Ahmad Eid Nazzal
المؤلفKamar, Mohd Ragheb Abou
المؤلفGoravey, Wael
المؤلفOmar, Amr Salah
المؤلفAbukhattab, Mohammed
المؤلفKhatib, Mohamad Yahya
المؤلفMohamedali, Mohamed Gaafar
المؤلفAlMaslamani, Muna A. Rahman
المؤلفAlemadi, Samar
تاريخ الإتاحة2022-12-15T07:16:19Z
تاريخ النشر2022
اسم المنشورMedicine (United States)
المصدرScopus
معرّف المصادر الموحدhttp://dx.doi.org/10.1097/MD.0000000000030843
معرّف المصادر الموحدhttp://hdl.handle.net/10576/37272
الملخصIntroduction: Colchicine acts upstream in the cytokines cascade by inhibiting the nod-like receptor protein 3 (NLRP3) inflammasome while interleukin 6 (IL-6) receptor antagonists, such as tocilizumab, block the end result of the cytokines cascade. Hence, adding colchicine to tocilizumab with the aim of blocking the early and end products of the cytokines cascade, might reduce the risk of developing cytokine storm. Methods and analysis: We aim to conduct an open-label randomized controlled trial to evaluate the efficacy and safety of adding colchicine to tocilizumab among patients with severe COVID-19 pneumonia to reduce the rate of invasive mechanical ventilation and mortality. We will include patients with severe COVID-19 pneumonia who received tocilizumab according to our local guidelines. Enrolled patients will be then randomized in 1:1 to colchicine versus no colchicine. Patients will be followed up for 30 days. The primary outcome is the rate of invasive mechanical ventilation and will be determined using Cox proportional hazard model. Discussion: Given colchicine's ease of use, low cost, good safety profile, and having different anti-inflammatory mechanism of action than other IL-6 blockade, colchicine might serve as a potential anti-inflammatory agent among patients with severe COVID-19 pneumonia. This study will provide valuable insights on the use of colchicine in severe COVID-19 when added to IL-6 antagonists. Ethics and dissemination: The Medical Research Center and Institutional Review Board at Hamad Medical Corporation in Qatar approved the study protocol (MRC-01-21-299). Results of the analysis will be submitted for publication in a peer-reviewed journal. 2022 Lippincott Williams and Wilkins. All rights reserved.
اللغةen
الناشرLippincott Williams and Wilkins
الموضوعcolchicine
COVID-19
IL-6 antagonists
severe pneumonia
tocilizumab
العنوانAdding colchicine to tocilizumab in hospitalized patients with severe COVID-19 pneumonia: An open-label randomized controlled trial
النوعArticle
الصفحاتE30618
رقم العدد39
رقم المجلد101
dc.accessType Open Access


الملفات في هذه التسجيلة

Thumbnail

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة